Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study

The Lancet Oncology

Volumn 12, Issue 9, 2011, Pages 880-890

  Castle, Philip E ^a   Stoler, Mark H ^b   Wright, Thomas C ^c   Sharma, Abha ^d   Wright, Teresa L ^d   Behrens, Catherine M ^d  

^a American Society for Clinical Pathology   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c Columbia University School of Medicine ^*  (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOPSY; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DISEASE COURSE; DNA SCREENING; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TESTING; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 80052388064     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70188-7     Document Type: Article

References (53)

1. Cervical cancer screening 2005, International Agency for Research on Cancer, International Agency for Research on Cancer Press, Lyon.
2. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Insinga RP, Dasbach EJ, Elbasha EH Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23:1107-1122.
4. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804.
5. Bulkmans NWJ, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257. the New Technologies for Cervical Cancer screening (NTCC) Working Group.
7. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
8. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
9. Kjaer SK, Frederiksen K, Munk C, Iftner T Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
10. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95:46-52.
11. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12:663-672.
12. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004, 100:1035-1044.
13. Liu S, Semenciw R, Probert A, Mao Y Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001, 11:24-31.
14. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005, 14:2191-2199.
15. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197:346-355.
16. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
17. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol 2011, 121:309-313.
18. de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056. on behalf of the Retrospective International Survey and HPV Time Trends Study Group.
19. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol 2009, 47:3344-3347.
20. Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TL High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011, 135:468-475.
21. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens CM, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of high-risk HPV-positive cytology-negative women. Am J Clin Pathol (in press).
22. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
23. Kurman RJ, Ellenson LH, Ronnett BM Blaustein's pathology of the female genital tract 2002, Springer, New York, NY. 5th edn.
24. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses (draft guidance) US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Device and Radiological HealthCenter for Device and Radiological Health, (accessed Aug 4, 2011). http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM181511.pdf.
25. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007, 11:223-239.
26. Castle PE, Stoler MH, Solomon D, Schiffman M The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007, 127:805-815.
27. Castle PE, Schiffman M, Wheeler CM, Solomon D Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113:18-25.
28. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007, 26:441-446.
29. Cervista HPV HR test instructions for use 2009, Third Wave Technologies, Third Wave Technologies, Madison, WI.
30. HC2 high-risk HPV DNA test (package insert) 2007, Qiagen, Qiagen, Gaithersburg, MD.
31. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003, 188:1383-1392. ALTS Group.
32. Zhou XH, Obuchowski NA, Obuchowski DM Statistical methods in diagnostic medicine 2002, John Wiley and Sons, New York, NY.
33. Leisenring W, Alonzo T, Pepe MS Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics 2000, 56:345-351.
34. Chemick M Bootstrapping methods: a practitioner's guide 1999, Wiley Interscience, New York, NY.
35. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
36. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
37. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
38. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
39. Castle PE, Fetterman B, Lorey T, Poitras N, Kinney W Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010, 115:243-248.
40. Cox JT History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol 2009, 45(suppl 1):S3-12.
41. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007, 197:356e1-356e6.
42. Katki HA, Wacholder S, Solomon D, Castle PE, Schiffman M Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol 2009, 10:1022-1023.
43. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
44. Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004, 103:304-309.
45. Sasieni P, Castle PE, Cuzick J Further analysis of the ARTISTIC trial. Lancet Oncol 2009, 10:841-842.
46. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
47. HPV genotyping clinical update 2009 American Society for Colposcopy and Cervical Pathology, (accessed Aug 4, 2011). http://www.asccp.org/ConsensusGuidelines/HPVGenotypingClinicalUpdate/tabid/5963/Default.aspx.
48. Castle PE, Fetterman B, Thomas Cox J, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010, 116:76-84.
49. Stoler MH, Schiffman M Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505.
50. Castle PE, Cox JT, Jeronimo J, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol 2008, 111:847-856.
51. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010, 34:1077-1087.
52. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10:321-322. on behalf of the WHO International Agency for Research on Cancer Monograph Working Group.
53. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol 2010, 119:237-242.